<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070757</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-008</org_study_id>
    <secondary_id>CXA-NP-11-04</secondary_id>
    <secondary_id>163338</secondary_id>
    <secondary_id>MK-7625A-008</secondary_id>
    <nct_id>NCT02070757</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)</brief_title>
  <acronym>ASPECT-NP</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, prospective, randomized study of intravenous (IV)
      ceftolozane/tazobactam versus IV meropenem in the treatment of adult participants with either
      ventilator-associated bacterial pneumonia (VABP) or ventilated hospital-acquired bacterial
      pneumonia (HABP). The primary objective is to demonstrate the non-inferiority of
      ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial
      pneumonia (VNP) based on the difference in Day 28 all-cause mortality rates in the
      Intent-to-treat (ITT) population using a non-inferiority margin of 10%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2014</start_date>
  <completion_date type="Actual">June 6, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in stratified adult participants with ventilated nosocomial pneumonia (VNP) (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) based on the difference in all-cause mortality rates in the intent to treat (ITT) population using a non-inferiority margin of 10%. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population</measure>
    <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
    <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) at the TOC visit (7 to 14 days after the end-of-therapy [EOT] visit) using a non-inferiority margin of 12.5%. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>To compare the all cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in microbiological intent-to-treat (mITT) population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</measure>
    <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
    <description>To compare the clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) at the TOC visit in the CE population. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population</measure>
    <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
    <description>To compare the per-participant microbiological response rates of ceftolozane/tazobactam versus meropenem at the TOC visit in the microbiologically evaluable (ME) population. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the TOC visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (&gt;=10 Isolates at Baseline)</measure>
    <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
    <description>To compare the percentage of participants with a microbiological outcome of eradication or presumed eradication, by pathogen. The microbiological outcome was classified as &quot;eradication&quot;, &quot;presumed eradication&quot;, &quot;persistence&quot;, 'presumed persistence&quot;, &quot;indeterminate&quot; or &quot;recurrence.&quot; &quot;Eradication&quot; was defined as a ≥1- log reduction in bacterial burden of the original baseline LRT pathogen AND a per pathogen count of ≤10^4 colony-forming unit (CFU)/mL for endotracheal aspirate (ETA) or sputum specimens, ≤10^3 CFU/mL for a bronchoalveolar lavage (BAL) specimen, or ≤10^2 CFU/mL for a protected brush specimen (PBS) from a follow-up LRT culture. Presumed eradication was defined as an absence of material to culture (e.g. inability to obtain a culture in an extubated patient) in a patient deemed a clinical cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>To compare the all cause mortality rates of participants (ceftolozane/tazobactam versus meropenem arms). Participants whose Day 14 mortality outcomes are missing or unknown are analysed as deceased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population</measure>
    <time_frame>Within 24 hours after last dose of study drug (Up to ~Day 15)</time_frame>
    <description>To compare the clinical response rates at the EOT visit for ceftolozane/tazobactam versus meropenem. Clinical response at the EOT visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population</measure>
    <time_frame>Within 24 hours after last dose of study drug (Up to ~Day 15)</time_frame>
    <description>To compare the microbiological response rates of ceftolozane/tazobactam versus meropenem at the EOT visit. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the EOT visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population</measure>
    <time_frame>28 to 35 days after the last dose of study drug (Up to ~Day 50)</time_frame>
    <description>To compare the clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in the CE population. Clinical response at the LFU visit will be classified as sustained cure, relapse, or indeterminate only in participants deemed a clinical cure at the TOC visit. A favorable clinical response is &quot;sustained clinical cure.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Report 1 or More Adverse Event (AE)</measure>
    <time_frame>Up to 35 days after last dose of study drug (Up to ~Day 50)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 35 days after last dose of study drug (Up to ~Day 50)</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after the first dose of study drug (Up to ~Day 15)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">726</enrollment>
  <condition>Healthcare-Associated Pneumonia</condition>
  <condition>Ventilator-Associated Pneumonia</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/tazobactam</intervention_name>
    <description>Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.</description>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.</description>
    <arm_group_label>Meropenem</arm_group_label>
    <other_name>MERREM® IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adult participants diagnosed with either VABP or ventilated HABP requiring IV
             antibiotic therapy;

          -  Intubated and on mechanical ventilation at the time of randomization;

          -  New or progressive infiltrate on chest radiography consistent with pneumonia;

          -  Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial
             pneumonia.

        Key Exclusion Criteria:

          -  History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics;

          -  Prior non-study antibiotics for &gt; 24 hours;

          -  Gram stain of lower respiratory tract specimen showing only gram positive bacteria;

          -  Active immunosuppression;

          -  End-stage renal disease or requirement for dialysis;

          -  Expected survival &lt; 72 hours;

          -  Severe confounding respiratory condition (i.e., chest trauma with paradoxical
             respiration);

          -  Known or suspected community-acquired bacterial pneumonia.

          -  Anticipated concomitant use of any of the following medications during the course of
             study therapy: valproic acid or divalproex sodium. Anticipated concomitant use of
             serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin 5-HT1 receptor
             agonists (triptans), meperidine, or buspirone during the course of linezolid
             treatment.

          -  Receipt of a monoamine oxidase inhibitor within 14 days prior to the first dose of
             study drug or anticipated concomitant use during the course of linezolid therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan;56(1):56-66. doi: 10.1002/jcph.566. Epub 2015 Aug 25.</citation>
    <PMID>26096377</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>May 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02070757/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 263 sites were opened for enrollment with the majority of participants recruited from sites in eastern Europe.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by diagnosis (ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) and by age (&lt;65 or ≥65 years). All participants randomized were included in the intent-to-treat (ITT) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
        </group>
        <group group_id="P2">
          <title>Meropenem</title>
          <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="364"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Participants</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="359"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged from Study Hospital</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
        </group>
        <group group_id="B2">
          <title>Meropenem</title>
          <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="362"/>
            <count group_id="B2" value="364"/>
            <count group_id="B3" value="726"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="16.7"/>
                    <measurement group_id="B2" value="59.5" spread="17.2"/>
                    <measurement group_id="B3" value="60.0" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="601"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian Or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian Or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28</title>
        <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in stratified adult participants with ventilated nosocomial pneumonia (VNP) (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) based on the difference in all-cause mortality rates in the intent to treat (ITT) population using a non-inferiority margin of 10%. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
        <time_frame>Day 28</time_frame>
        <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28</title>
          <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in stratified adult participants with ventilated nosocomial pneumonia (VNP) (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) based on the difference in all-cause mortality rates in the intent to treat (ITT) population using a non-inferiority margin of 10%. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
          <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="18.83" upper_limit="27.39"/>
                    <measurement group_id="O2" value="25.3" lower_limit="19.96" upper_limit="28.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Meropenem minus ceftolozane/tazobactam. For ceftolozane/tazobactam to be non-inferior to meropenem the lower bound of a 2-sided 95% confidence interval (CI) for the difference between treatment groups had to be ≥ -10%.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>7.39</ci_upper_limit>
            <estimate_desc>The % difference between groups is the weighted proportion difference using MRc stratum weights for diagnosis and age categories. The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population</title>
        <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) at the TOC visit (7 to 14 days after the end-of-therapy [EOT] visit) using a non-inferiority margin of 12.5%. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
        <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
        <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Intent-to-Treat (ITT) Population</title>
          <description>To demonstrate the non-inferiority of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) at the TOC visit (7 to 14 days after the end-of-therapy [EOT] visit) using a non-inferiority margin of 12.5%. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.</description>
          <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="49.47" upper_limit="59.60"/>
                    <measurement group_id="O2" value="53.3" lower_limit="48.44" upper_limit="58.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Clinical Response difference is calculated as ceftolozane/tazobactam minus meropenem. For ceftolozane/tazobactam to be non-inferior to meropenem the lower bound of a 2-sided 95% confidence interval (CI) for the difference between treatment groups had to be ≥ -12.5%.</non_inferiority_desc>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>8.29</ci_upper_limit>
            <estimate_desc>The % difference between groups is the weighted proportion difference using MRc stratum weights for diagnosis and age categories. The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28</title>
        <description>To compare the all cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in microbiological intent-to-treat (mITT) population.</description>
        <time_frame>Day 28</time_frame>
        <population>The mITT population was a subset of the ITT population that included any participant who received any amount of study drug and had at least 1 bacterial respiratory pathogen isolated from the baseline LRT culture that was susceptible to at least 1 of the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population - Day 28</title>
          <description>To compare the all cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in microbiological intent-to-treat (mITT) population.</description>
          <population>The mITT population was a subset of the ITT population that included any participant who received any amount of study drug and had at least 1 bacterial respiratory pathogen isolated from the baseline LRT culture that was susceptible to at least 1 of the study drugs.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="15.12" upper_limit="24.50"/>
                    <measurement group_id="O2" value="25.5" lower_limit="18.89" upper_limit="29.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.83</ci_lower_limit>
            <ci_upper_limit>11.75</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</title>
        <description>To compare the clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) at the TOC visit in the CE population. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
        <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
        <population>The CE population was a subset of the ITT population that included any participant who received study drug, adhered to the study protocol through the TOC visit, and had an evaluable clinical outcome (either Cure or Failure) at the TOC visit (or were classified as a clinical failure prior to the TOC visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Clinical Cure at the Test-of-Cure (TOC) Visit in the Clinically Evaluable (CE) Population</title>
          <description>To compare the clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP (participants with either ventilator-associated bacterial pneumonia [VABP] or ventilated hospital-acquired bacterial pneumonia [HABP]) at the TOC visit in the CE population. Clinical response at the TOC visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate unless the clinical outcome at the EOT visit was failure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
          <population>The CE population was a subset of the ITT population that included any participant who received study drug, adhered to the study protocol through the TOC visit, and had an evaluable clinical outcome (either Cure or Failure) at the TOC visit (or were classified as a clinical failure prior to the TOC visit).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" lower_limit="57.50" upper_limit="70.11"/>
                    <measurement group_id="O2" value="64.7" lower_limit="58.83" upper_limit="71.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.21</ci_lower_limit>
            <ci_upper_limit>7.67</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population</title>
        <description>To compare the per-participant microbiological response rates of ceftolozane/tazobactam versus meropenem at the TOC visit in the microbiologically evaluable (ME) population. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the TOC visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
        <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
        <population>The ME population was a subset of the mITT population that included any participants who adhered to the study protocol through the TOC visit, had an evaluable clinical outcome (Cure or Failure) at the TOC visit and had at least 1 bacterial respiratory pathogen (at the appropriate CFU/mL threshold) isolated from the baseline LRT culture.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population</title>
          <description>To compare the per-participant microbiological response rates of ceftolozane/tazobactam versus meropenem at the TOC visit in the microbiologically evaluable (ME) population. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the TOC visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
          <population>The ME population was a subset of the mITT population that included any participants who adhered to the study protocol through the TOC visit, had an evaluable clinical outcome (Cure or Failure) at the TOC visit and had at least 1 bacterial respiratory pathogen (at the appropriate CFU/mL threshold) isolated from the baseline LRT culture.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="61.37" upper_limit="77.55"/>
                    <measurement group_id="O2" value="62.7" lower_limit="54.12" upper_limit="71.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.11</ci_lower_limit>
            <ci_upper_limit>18.93</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (&gt;=10 Isolates at Baseline)</title>
        <description>To compare the percentage of participants with a microbiological outcome of eradication or presumed eradication, by pathogen. The microbiological outcome was classified as &quot;eradication&quot;, &quot;presumed eradication&quot;, &quot;persistence&quot;, 'presumed persistence&quot;, &quot;indeterminate&quot; or &quot;recurrence.&quot; &quot;Eradication&quot; was defined as a ≥1- log reduction in bacterial burden of the original baseline LRT pathogen AND a per pathogen count of ≤10^4 colony-forming unit (CFU)/mL for endotracheal aspirate (ETA) or sputum specimens, ≤10^3 CFU/mL for a bronchoalveolar lavage (BAL) specimen, or ≤10^2 CFU/mL for a protected brush specimen (PBS) from a follow-up LRT culture. Presumed eradication was defined as an absence of material to culture (e.g. inability to obtain a culture in an extubated patient) in a patient deemed a clinical cure.</description>
        <time_frame>7 to 14 days after last dose of study drug (Up to ~Day 30)</time_frame>
        <population>The ME population included any participants in the mITT who adhered to the protocol, had an evaluable clinical outcome at TOC and at least 1 pathogen isolated from the baseline LRT culture at the appropriate CFU/mL threshold. The number analyzed per pathogen represents the number of participants in the ME population with that specific pathogen.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Response of Eradication or Presumed Eradication, by Pathogen, at the Test-of-Cure (TOC) Visit in the Microbiologically Evaluable (ME) Population (&gt;=10 Isolates at Baseline)</title>
          <description>To compare the percentage of participants with a microbiological outcome of eradication or presumed eradication, by pathogen. The microbiological outcome was classified as &quot;eradication&quot;, &quot;presumed eradication&quot;, &quot;persistence&quot;, 'presumed persistence&quot;, &quot;indeterminate&quot; or &quot;recurrence.&quot; &quot;Eradication&quot; was defined as a ≥1- log reduction in bacterial burden of the original baseline LRT pathogen AND a per pathogen count of ≤10^4 colony-forming unit (CFU)/mL for endotracheal aspirate (ETA) or sputum specimens, ≤10^3 CFU/mL for a bronchoalveolar lavage (BAL) specimen, or ≤10^2 CFU/mL for a protected brush specimen (PBS) from a follow-up LRT culture. Presumed eradication was defined as an absence of material to culture (e.g. inability to obtain a culture in an extubated patient) in a patient deemed a clinical cure.</description>
          <population>The ME population included any participants in the mITT who adhered to the protocol, had an evaluable clinical outcome at TOC and at least 1 pathogen isolated from the baseline LRT culture at the appropriate CFU/mL threshold. The number analyzed per pathogen represents the number of participants in the ME population with that specific pathogen.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gram-Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="60.91" upper_limit="77.60"/>
                    <measurement group_id="O2" value="62.4" lower_limit="53.35" upper_limit="70.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="61.61" upper_limit="90.15"/>
                    <measurement group_id="O2" value="55.3" lower_limit="39.71" upper_limit="69.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterobacteriaceae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="58.06" upper_limit="77.64"/>
                    <measurement group_id="O2" value="65.6" lower_limit="55.28" upper_limit="74.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="58.10" upper_limit="90.34"/>
                    <measurement group_id="O2" value="73.9" lower_limit="53.53" upper_limit="87.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="56.43" upper_limit="82.83"/>
                    <measurement group_id="O2" value="66.7" lower_limit="52.54" upper_limit="78.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="35.38" upper_limit="84.83"/>
                    <measurement group_id="O2" value="70.0" lower_limit="39.68" upper_limit="89.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="64.61" upper_limit="98.51"/>
                    <measurement group_id="O2" value="50.0" lower_limit="21.52" upper_limit="78.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterobacter cloacae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="25.05" upper_limit="84.18"/>
                    <measurement group_id="O2" value="75.0" lower_limit="40.93" upper_limit="92.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella oxytoca</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="52.91" upper_limit="97.76"/>
                    <measurement group_id="O2" value="57.1" lower_limit="25.05" upper_limit="84.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serratia marcescens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="11.76" upper_limit="76.93"/>
                    <measurement group_id="O2" value="50.0" lower_limit="18.76" upper_limit="81.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acinetobacter baumannii</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="9.68" upper_limit="70.00"/>
                    <measurement group_id="O2" value="80.0" lower_limit="37.55" upper_limit="96.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14</title>
        <description>To compare the all cause mortality rates of participants (ceftolozane/tazobactam versus meropenem arms). Participants whose Day 14 mortality outcomes are missing or unknown are analysed as deceased.</description>
        <time_frame>Day 14</time_frame>
        <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population - Day 14</title>
          <description>To compare the all cause mortality rates of participants (ceftolozane/tazobactam versus meropenem arms). Participants whose Day 14 mortality outcomes are missing or unknown are analysed as deceased.</description>
          <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="10.48" upper_limit="17.57"/>
                    <measurement group_id="O2" value="12.9" lower_limit="9.31" upper_limit="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.41</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population</title>
        <description>To compare the clinical response rates at the EOT visit for ceftolozane/tazobactam versus meropenem. Clinical response at the EOT visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate.</description>
        <time_frame>Within 24 hours after last dose of study drug (Up to ~Day 15)</time_frame>
        <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Clinical Cure at the End-of-Therapy (EOT) Visit in the Intent-to-Treat (ITT) Population</title>
          <description>To compare the clinical response rates at the EOT visit for ceftolozane/tazobactam versus meropenem. Clinical response at the EOT visit was defined as cure (complete resolution with no new signs of VNP), failure (progression, relapse or recurrence of VNP) or indeterminate (no evaluable study data). A favorable clinical response is a clinical cure. A missing clinical response will be considered indeterminate.</description>
          <population>The ITT population consisted of all randomized participants with documented informed consent, regardless of whether or not they received study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="61.38" upper_limit="71.03"/>
                    <measurement group_id="O2" value="66.8" lower_limit="62.31" upper_limit="71.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.67</ci_lower_limit>
            <ci_upper_limit>6.04</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population</title>
        <description>To compare the microbiological response rates of ceftolozane/tazobactam versus meropenem at the EOT visit. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the EOT visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
        <time_frame>Within 24 hours after last dose of study drug (Up to ~Day 15)</time_frame>
        <population>The ME population was a subset of the mITT population that included any participants who adhered to the study protocol through the TOC visit, had an evaluable clinical outcome (Cure or Failure) at the TOC visit and had at least 1 bacterial respiratory pathogen (at the appropriate CFU/mL threshold) isolated from the baseline LRT culture.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Per-Participant Microbiological Response of Cure or Presumed Cure at the End-of-Therapy (EOT) Visit in the Microbiologically Evaluable (ME) Population</title>
          <description>To compare the microbiological response rates of ceftolozane/tazobactam versus meropenem at the EOT visit. The per-participant microbiological response will be determined based on the individual microbiological outcomes for each baseline pathogen. A microbiological response at the EOT visit was defined as cure (baseline pathogens eradicated), failure (baseline pathogen is persistent) or indeterminate (no evaluable respiratory material). A favorable microbiological response is a microbiological cure or presumed cure. The data-as-observed (DAO) approach was used where participants with missing clinical responses, including indeterminate outcomes, are excluded from the analysis population.</description>
          <population>The ME population was a subset of the mITT population that included any participants who adhered to the study protocol through the TOC visit, had an evaluable clinical outcome (Cure or Failure) at the TOC visit and had at least 1 bacterial respiratory pathogen (at the appropriate CFU/mL threshold) isolated from the baseline LRT culture.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="71.51" upper_limit="86.33"/>
                    <measurement group_id="O2" value="78.8" lower_limit="70.25" upper_limit="84.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>12.02</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population</title>
        <description>To compare the clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in the CE population. Clinical response at the LFU visit will be classified as sustained cure, relapse, or indeterminate only in participants deemed a clinical cure at the TOC visit. A favorable clinical response is &quot;sustained clinical cure.&quot;</description>
        <time_frame>28 to 35 days after the last dose of study drug (Up to ~Day 50)</time_frame>
        <population>The CE population was a subset of the ITT population that included any participant who received study drug, adhered to the study protocol through the TOC visit, and had an evaluable clinical outcome (either Cure or Failure) at the TOC visit (or were classified as a clinical failure prior to the TOC visit).</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Clinical Cure at the Late Follow-up (LFU) Visit in the Clinically Evaluable (CE) Population</title>
          <description>To compare the clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in the CE population. Clinical response at the LFU visit will be classified as sustained cure, relapse, or indeterminate only in participants deemed a clinical cure at the TOC visit. A favorable clinical response is &quot;sustained clinical cure.&quot;</description>
          <population>The CE population was a subset of the ITT population that included any participant who received study drug, adhered to the study protocol through the TOC visit, and had an evaluable clinical outcome (either Cure or Failure) at the TOC visit (or were classified as a clinical failure prior to the TOC visit).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="90.10" upper_limit="97.99"/>
                    <measurement group_id="O2" value="51.6" lower_limit="85.86" upper_limit="95.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage of Participants</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The % difference is the weighted proportion difference using Mehrotra-Railkar continuity-corrected-minimum risk (MRc) stratum weights for strata of diagnosis (VABP, ventilated HABP) and age (&lt;65, &gt;=65) categories.</non_inferiority_desc>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.38</ci_lower_limit>
            <ci_upper_limit>10.44</ci_upper_limit>
            <estimate_desc>The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Report 1 or More Adverse Event (AE)</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
        <time_frame>Up to 35 days after last dose of study drug (Up to ~Day 50)</time_frame>
        <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Report 1 or More Adverse Event (AE)</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
          <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Serious Adverse Event (SAE)</title>
        <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
        <time_frame>Up to 35 days after last dose of study drug (Up to ~Day 50)</time_frame>
        <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Serious Adverse Event (SAE)</title>
          <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
          <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
        <time_frame>Up to 14 days after the first dose of study drug (Up to ~Day 15)</time_frame>
        <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
          </group>
          <group group_id="O2">
            <title>Meropenem</title>
            <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Drug Due to an Adverse Event (AE)</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
          <population>All safety analyses were based on a subset of the ITT population (the Safety Population), which included randomized participants who received any amount (i.e., full or partial dose) of study drug. All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 35 days after last dose of study drug (Up to ~Day 50)</time_frame>
      <desc>All safety analyses were based on a subset of the ITT population who received any amount (i.e., full or partial dose) of study drug (the Safety Population). All participants received their randomly assigned treatments, and no participants with important deviations were excluded from the safety population. Discontinuations due to adverse events (AEs) include deaths.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Participants receive 3000 mg ceftolozane/tazobactam (comprising 2000 mg ceftolozane and 1000 mg tazobactam) administered as an IV infusion every 8 hours (q8h).</description>
        </group>
        <group group_id="E2">
          <title>Meropenem</title>
          <description>Participants receive 1000 mg meropenem administered as an IV infusion q8h.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="361"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral arteriovenous malformation haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>CNS ventriculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Endotoxaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Tracheal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Apallic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Brain midline shift</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="361"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebral vasoconstriction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Mediastinal effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="361"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Neurogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="361"/>
                <counts group_id="E2" events="45" subjects_affected="38" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="361"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="361"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="361"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor will review proposed publication within forty five (45) calendar days and reserves the right to defer such publication an additional forty five (45) calendar days to protect Sponsor’s intellectual property as applicable. If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of Trial at all participating sites, Principal Investigator is free to publish separately, subject to the other requirements of this Agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

